These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35686412)

  • 21. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Cai Z; Zhan P; Song Y; Liu H; Lv T
    Transl Lung Cancer Res; 2022 Aug; 11(8):1555-1566. PubMed ID: 36090645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.
    Zhang J; Han W; Guo J; Zhang C; Cao L; Peng L; Han X; Wang Z
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):42. PubMed ID: 38280966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
    Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
    Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
    Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis.
    Wu J; Ni T; Deng R; Li Y; Zhong Q; Tang F; Zhang Q; Fang C; Xue Y; Zha Y; Zhang Y
    Front Immunol; 2023; 14():1065510. PubMed ID: 36993952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.
    Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
    Int Immunopharmacol; 2021 Jul; 96():107594. PubMed ID: 33798808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].
    Shu C; Zhu D; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis.
    Xu J; Wu Y; Xu Y; Qiu Y; Li X; Song Y; Zhang L
    Front Immunol; 2022; 13():802672. PubMed ID: 35173721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.
    Li S; Xu Q; Dai X; Zhang X; Huang M; Huang K; Shi D; Wang J; Liu L
    Ann Surg Oncol; 2023 Jun; 30(6):3594-3602. PubMed ID: 36795255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of treatment-related adverse events and wound complications of surgical resection after neoadjuvant chemoimmunotherapy for non-small cell lung cancer.
    Li Y; Hu X; Zhang R; Wu N; Xia Q; Gu P
    Int Wound J; 2024 Mar; 21(3):e14831. PubMed ID: 38484730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
    Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
    J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.